ArQule, Inc. to Report Third Quarter 2009 Financial Results on Thursday, November 5, 2009
More News related to ARQL
- Drug Discovery Capabilities of ArQule Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference
- ArQule, Inc. to Present at Lazard Capital Markets Sixth Annual Healthcare Conference on November 17, 2009
- ArQule (ARQL) Posts Q3 Loss of $0.18, Beats Estimates; Reaffirms Guidance
- ArQule Announces Third Quarter Fiscal 2009 Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Press Releases
- Quicksilver Resources (KWK) Granted Motion for Partial Summary by Texas in BreitBurn (BBEP) Lawsuit
- American International Group (AIG) Implementing Benmosche's Compensation Agreement
- Sun American (SAMB) Receives Listing Rule 5450 Notification from NASDAQ
- Solutia (SOA) To Discontinue Manufacturing at its Plant in Cologne, Germany
- General Dynamics (GD) Business Unit Awarded $2.2B U.S. Army SAC Contract for 724 LAV's
Conference call and web cast scheduled for 9:00 a.m. eastern time
WOBURN, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the third quarter of 2009 in a press release to be issued on Thursday, November 5, 2009 at 7:00 a.m. eastern time. The Company will host a conference call and web cast to discuss these results at 9:00 a.m. eastern time on that day.
Conference call details
Date: Thursday, November 5, 2009 Time: 9:00 a.m. ET Conference Call Numbers Domestic: 866-770-7125 International: 617-213-8066 Participant Passcode: 76724058 Web cast: http://www.arqule.com
A replay of the conference call will be available beginning at 12:00 p.m. on November 5, 2009 for seven days and can be accessed by dialing toll-free 888-286-8010 and outside the U.S. 1-617-801-6888. The access code is 86035092.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. An additional clinical-stage program includes compounds that activate the cell's DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company's pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP(TM)) are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
Source: ArQule
Related Categories
Press ReleasesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
